A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
Hers breaks down the winter blues, what causes them, and research-backed tips for handling this seasonal mood change.
Explore how political divisiveness impacts mental health and amplifies high-functioning depression, and discover strategies ...
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.
NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...
(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback